Suppr超能文献

卵巢癌化疗方案变更后再次发生横纹肌溶解症:一例报告

Rhabdomyolysis Occurred Again after Changing Chemotherapy Regimens in Ovarian Cancer: A Case Report.

作者信息

Cao Shaocong, Peng Tao

机构信息

Shenzhen Hospital of Guangzhou University of Chinese Medicine, Shenzhen, China.

出版信息

Case Rep Oncol. 2024 Nov 19;17(1):1322-1326. doi: 10.1159/000542103. eCollection 2024 Jan-Dec.

Abstract

INTRODUCTION

The incidence of chemotherapy-induced rhabdomyolysis is rare, but it is a syndrome that may cause death and should be paid attention to clinically.

CASE PRESENTATION

Here, we report a case of rhabdomyolysis in an ovarian cancer patient after chemotherapy. After the symptoms were relieved, the chemotherapy regimen was changed, and rhabdomyolysis occurred again.

CONCLUSION

The occurrence of rhabdomyolysis is mainly caused by certain specific chemotherapy drugs such as gemcitabine and paclitaxel and is not closely related to other factors such as the patient's constitution or genetic factors. And the occurrence of rhabdomyolysis can be caused by conventional doses of drugs rather than high dose. If rhabdomyolysis occurs and is completely relieved, chemotherapy may be considered again depending on the patient's condition and physical condition. However, caution should be exercised in selecting drugs to avoid recurrence of rhabdomyolysis, and the condition should be closely monitored.

摘要

引言

化疗诱导的横纹肌溶解症发病率很低,但它是一种可能导致死亡的综合征,临床上应予以关注。

病例报告

在此,我们报告1例卵巢癌患者化疗后发生横纹肌溶解症的病例。症状缓解后更改了化疗方案,横纹肌溶解症再次发生。

结论

横纹肌溶解症的发生主要由某些特定化疗药物如吉西他滨和紫杉醇引起,与患者体质或遗传因素等其他因素无密切关系。而且常规剂量而非高剂量药物即可导致横纹肌溶解症的发生。如果发生横纹肌溶解症且完全缓解,可根据患者病情和身体状况考虑再次进行化疗。然而,选择药物时应谨慎,以避免横纹肌溶解症复发,并应密切监测病情。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/616f/11575922/615d6d09ac78/cro-2024-0017-0001-542103_F01.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验